世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
ワクチン受託製造市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Vaccine Contract Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global vaccine contract manufacturing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping i... もっと見る
サマリーThe global vaccine contract manufacturing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols. Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, workflow and application. Breakup by Vaccine Type: Attenuated Inactivated Subunit-based Toxoid-based DNA-based Breakup by Workflow: Downstream Fill and Finish Operations Analytical and QC studies Packaging Upstream Mammalian Expression Systems Bacterial Expression Systems Yeast Expression Systems Baculovirus/Insect Expression Systems Others Breakup by Application: Human Use Veterinary Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc. Key Questions Answered in This Report: How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global vaccine contract manufacturing market? What are the key regional markets? What is the breakup of the market based on the vaccine type? What is the breakup of the market based on the workflow? What is the breakup of the market based on the application? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global vaccine contract manufacturing market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Vaccine Contract Manufacturing Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Vaccine Type 6.1 Attenuated 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Inactivated 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Subunit-based 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Toxoid-based 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 DNA-based 6.5.1 Market Trends 6.5.2 Market Forecast 7 Market Breakup by Workflow 7.1 Downstream 7.1.1 Market Trends 7.1.2 Key Segments 7.1.2.1 Fill and Finish Operations 7.1.2.2 Analytical and QC studies 7.1.2.3 Packaging 7.1.3 Market Forecast 7.2 Upstream 7.2.1 Market Trends 7.2.2 Key Segments 7.2.2.1 Mammalian Expression Systems 7.2.2.2 Bacterial Expression Systems 7.2.2.3 Yeast Expression Systems 7.2.2.4 Baculovirus/Insect Expression Systems 7.2.2.5 Others 7.2.3 Market Forecast 8 Market Breakup by Application 8.1 Human Use 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Veterinary 8.2.1 Market Trends 8.2.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Ajinomoto Co. Inc. 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Albany Molecular Research Inc 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 SWOT Analysis 14.3.3 Catalent Inc 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.) 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.) 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.6 Fujifilm Holdings Corporation 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 ICON plc 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 IDT Biologika GmbH 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.9 Lonza Group AG 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Merck KGaA 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis 14.3.11 Pharmaceutical Product Development LLC 14.3.11.1 Company Overview 14.3.11.2 Product Portfolio 14.3.11.3 Financials 14.3.11.4 SWOT Analysis 14.3.12 PRA Health Sciences Inc. 14.3.12.1 Company Overview 14.3.12.2 Product Portfolio 14.3.12.3 Financials
SummaryThe global vaccine contract manufacturing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols. Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, workflow and application. Breakup by Vaccine Type: Attenuated Inactivated Subunit-based Toxoid-based DNA-based Breakup by Workflow: Downstream Fill and Finish Operations Analytical and QC studies Packaging Upstream Mammalian Expression Systems Bacterial Expression Systems Yeast Expression Systems Baculovirus/Insect Expression Systems Others Breakup by Application: Human Use Veterinary Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc. Key Questions Answered in This Report: How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global vaccine contract manufacturing market? What are the key regional markets? What is the breakup of the market based on the vaccine type? What is the breakup of the market based on the workflow? What is the breakup of the market based on the application? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global vaccine contract manufacturing market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Vaccine Contract Manufacturing Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Vaccine Type 6.1 Attenuated 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Inactivated 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Subunit-based 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Toxoid-based 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 DNA-based 6.5.1 Market Trends 6.5.2 Market Forecast 7 Market Breakup by Workflow 7.1 Downstream 7.1.1 Market Trends 7.1.2 Key Segments 7.1.2.1 Fill and Finish Operations 7.1.2.2 Analytical and QC studies 7.1.2.3 Packaging 7.1.3 Market Forecast 7.2 Upstream 7.2.1 Market Trends 7.2.2 Key Segments 7.2.2.1 Mammalian Expression Systems 7.2.2.2 Bacterial Expression Systems 7.2.2.3 Yeast Expression Systems 7.2.2.4 Baculovirus/Insect Expression Systems 7.2.2.5 Others 7.2.3 Market Forecast 8 Market Breakup by Application 8.1 Human Use 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Veterinary 8.2.1 Market Trends 8.2.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Ajinomoto Co. Inc. 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Albany Molecular Research Inc 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 SWOT Analysis 14.3.3 Catalent Inc 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.) 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.) 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.6 Fujifilm Holdings Corporation 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 ICON plc 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 IDT Biologika GmbH 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.9 Lonza Group AG 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Merck KGaA 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis 14.3.11 Pharmaceutical Product Development LLC 14.3.11.1 Company Overview 14.3.11.2 Product Portfolio 14.3.11.3 Financials 14.3.11.4 SWOT Analysis 14.3.12 PRA Health Sciences Inc. 14.3.12.1 Company Overview 14.3.12.2 Product Portfolio 14.3.12.3 Financials
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（抗生物薬）の最新刊レポートIMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（vaccine）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/04 10:27 147.72 円 163.39 円 196.69 円 |
